Advancement in high dose therapy and autologous stem cell rescue in lymphoma

Table 2 High dose therapy followed by autologous stem cell transplantation in non-Hodgkin lymphoma

Ref.	Year	Patients (n)	Disease	Regimen	TRM (%)	ORR (%)	OS (%)	Follow-up (mo)
Kim et al[11]	2012	44	Chemosensitive-NHL	NEAM	2.9	79	64	24
Falzetti et al[12]	2012	45	HR NHL	TT-Vp-Car	4.4	77	71	60
William et al[13]	2014	42	R/R NHL	V-BEAM	0	87	91	12
Visani et al[14]	2011	43	R/R HL and NHL	BeEAM	0	82	81	18
Visani et al[15]	2014	43	R/R HL and NHL	BeEAM	0	72	88	41
Isidori et al[16]	2014	37	R/R NHL	BeEAM	2.7	88	94	9
Musso et al[17]	2010	84	R/R HL and NHL	FEAM	2.4	73	88	13
Kruger et al[19]	2012	16	R/R NHL	RIT + BEAM	6	94	75	44
Winter et al[20]	2009	44	R/R NHL	Z-BEAM	2.2	77	60	33
Shimoni et al[21]	2012	43	R/R NHL	Z-BEAM	0	97	91	24
Briones et al[22]	2014	30	R/R NHL	RIT + BEAM	3.5	70	63	31

HL: Hodgkin lymphoma; RIT: Radioimmunotherapy; BeEAM: Bendamustine, etoposide, ara-C, melphalan; FEAM: Fotemustine plus etoposide, cytarabine and melphalan; NEAM: Mitoxantrone, etoposide, cytarabine, and melphalan; NHL: Non-Hodgkin lymphoma; R/R: Relapsed/refractory; OS: Overall survival; TT-Vp-Car: Thiotepa, Vepeside, carmustine; V-BEAM: Velcade plus standard BEAM.